RxDoctor Payments Data

Isabelle Magana, PA

Medical · Salinas, CANPI 1417631771

Payments from drug & device makers

$3,967in general payments, 2019–2025

Across 85 payments — averaging $46.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Merck$364
  • Actelion Pharmaceuticals US, Inc.$243
  • E.r. Squibb & Sons, L.L.C.$183
  • Scpharmaceuticals Inc.$126
  • Bayer$115
  • plus $358 from 12 others

What the payments were for

  • Travel & lodging$1,92448%
  • Food & beverage$2,02351%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,967 in reported general payments places this provider in the 80th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$67,744
Medicare patients
396
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$107,196
JardianceEmpagliflozin60$65,776
EntrestoSacubitril/Valsartan37$57,438
FuroscixFurosemide11$54,319
Bumetanide67$6,230
Metoprolol Succinate127$1,710
Nitroglycerin39$1,323
Atorvastatin Calcium106$1,317
Furosemide147$1,192
Losartan Potassium109$1,022
Amiodarone Hcl39$1,019
Rosuvastatin Calcium53$991
Valsartan12$976
Midodrine Hcl19$661
Ezetimibe22$620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$107,196101 claims
NovartisEntresto$42$57,43837 claims
Scpharmaceuticals Inc.Furoscix$126$54,31911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 medical providers in California.

Other medical in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →